Discovery Laboratorie Kauf zu 2,30 $ Ziel 2,55 €

3. August 2010 Börsenschluss : 0,31 $ After Hours Last :
Net / Veränderung in%  $ 0,33

0,02 ( 6,45% )  After Hours High: $ 0,33
After Hours Band : 314.446 After Hours Low: $ 0,30

Erfahren Sie mehr über die After-Hours Trading Session. Trade Detail
After Hours
Time (ET) After Hours
Preis After Hours
Sagen Band
19.58 Uhr  $ 0,33  500
19.39 Uhr  0,3299 $  5000
19.39 Uhr  $ 0,33  7000
19.30 Uhr  0,3201 $  7400
19.30 Uhr  $ 0,32  42.600
19.28 Uhr  0,3201 $  2600
19.25 Uhr  0,3201 $  10.000
19.25 Uhr  0,3201 $  10.000
19.25 Uhr  $ 0,32  10.000
18.57 Uhr  $ 0,33  6800
18.55 Uhr  0,3289 $  5000
18.55 Uhr  $ 0,329  10.000
18.55 Uhr  $ 0,33  8500
18.26 Uhr  $ 0,32  5000
18.23 Uhr  0,3199 $  300
18.23 Uhr  0,3199 $  5000
18.05 Uhr  0,3189 $  5000
18.05 Uhr  $ 0,319  20.000
17.49 Uhr  $ 0,31  4400
17.47 Uhr  $ 0,31  26.300
17.47 Uhr  0,3099 $  3100
17.47 Uhr  $ 0,31  600
17.45 Uhr  $ 0,31  2600
17.43 Uhr  0,3099 $  500
17.36 Uhr  0,3099 $  1400
17.09 Uhr  $ 0,31  5100
16.39 Uhr  $ 0,30  36.100
16.36 Uhr  $ 0,30  1200
16.36 Uhr  $ 0,30  2500
16.34 Uhr  $ 0,30  20.000
16.29 Uhr  $ 0,30  9350
16.27 Uhr  $ 0,306  29.900
16.27 Uhr  0,3052 $  500
16.27 Uhr  $ 0,30  450
16.24 Uhr  $ 0,306  100
16.16 Uhr  0,3199 $  200
16.14 Uhr  0,3199 $  4500
16.07 Uhr  0,3149 $  1446
16.00 Uhr  0,3052 $  2000
16.00 Uhr  0,3052 $  500
16.00 Uhr  0,3052 $  1000

 

http://www.boardcentral.com/boards/DSCO

Securities Healthcare Conference

Warrington, PA — August 11, 2010 — Discovery Laboratories, Inc. (Nasdaq: DSCO)
announces today that Dr. Thomas F. Miller, Senior Vice President of Commercial & Corporate
Development of Discovery Labs, will present an overview of the Company at the 2010 Global
Hunter Securities Healthcare Conference taking place at the SCIC (Southern California Investor
Conference) on August 17, 2010 in Newport Beach, CA. The conference will be simultaneously
webcast over the Internet.
Dr. Miller is scheduled to present at 3:30 PM PDT (6:30 PM EDT) on Tuesday, August 17,
2010. The presentation will be available through a live audio webcast at
http://events.powerstream.net/002/00584/20100817_SCIC_Discovery/ or at Discovery Labs’
web site, www.discoverylabs.com. A replay of the audio webcast will be available on both
websites for sixty days.

http://www.discoverylabs.com/pr.php

du lernst es nicht ! VERGISS Discovery Labs und schau dir die Pipeline und den chart von Impax Labs (Nasdaq: IPXL) an !!  

Cooper becomes Discovery Labs CEO in realignment

http://www.bizjournals.com/philadelphia/stories/....html?surround=lfn

http://www.finanznachrichten.de/...and-board-from-five-to-six-020.htm

http://www.discoverylabs.com/2010pr/092110-PR.pdf

http://www.discoverylabs.com/2010pr/092210-PR.pdf

Hast du noch hoffnung für discovery Labs ? Bin in Hana bioscience (Hnab.ob) eingestiegen,was hälst du davon ?

MFG
Chali  

Laboratories

PharmaBio Development Inc. entered into an agreement Wednesday to invest an additional $500,000 in Discovery Laboratories Inc., a biotechnology company developing treatments for respiratory diseases.

Under the terms of the deal PharmaBio, the former strategic investing subsidiary of Quintiles Transnational Corp., purchased about 2.4 million shares of Discovery Labs’s (NASDAQ:DSCO) common stock and warrants to buy about 1.2 million shares of common stock.

Each common share, together with a related warrant to buy a half of a share of common stock, was sold at a unit price of 21 cents. The warrants have a five-year term and are exercisable at an exercise price of 27.3 cents per share of common stock.


Read more: PharmaBio increases stake in Discovery Laboratories - Philadelphia Business Journal

http://www.bizjournals.com/philadelphia/stories/....html?surround=lfn

http://www.finanznachrichten.de/...scovery-labs-names-new-ceo-020.htm

Hana ist eher Tod als Discovery Laboratorie

http://www.finanznachrichten.de/...ed-orphan-drug-designation-020.htm  

http://www.discoverylabs.com/2010pr/110210-PR.pdf

Discovery Labs Provides a Third Quarter 2010 Business and Financial Update  

http://www.discoverylabs.com/2010pr/110910-PR.pdf

November 15, 2010
Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference

http://www.discoverylabs.com/

Hana bio heisst ab morgen "Talon therapeutics" und wird das NDA in 2011 stellen ! Meinst du immer noch ,dass Hana dem Tode geweiht ist ? Ich denke eher DSCO ist zum Verrecken verdammt .....

MFG
Chali  

Discovery Labs (DSCO) Stock to Be Delisted from Nasdaq; Will Request Hearing

http://www.streetinsider.com/Corporate+News/...t+Hearing/6141584.html

December 7, 2010
Leading Proxy Advisory Firms Recommend that Discovery Labs’ Stockholders Vote “FOR” Important Proposals at Annual Meeting of Stockholders

December 7, 2010
Discovery Labs Aerosurf® Improves Lung Function and Reduces Inflammation in a Dose-dependent Fashion in Established Non-Clinical Model of Preterm Respiratory Distress Syndrome

http://www.discoverylabs.com/home.php

http://www.mysmartrend.com/news-briefs/...entum-looks-continue-dsco-3

NIH Awards Discovery Labs Fast Track SBIR Grant  to Support Development of Aerosolized KL4 Surfactant
 
 Date : 12/16/2010 @ 7:00AM
Source : GlobeNewswire Inc.
Stock  : Discovery Laboratories, Inc. (DSCO)
 
http://ih.advfn.com/p.php?pid=nmona&article=45679721  
 
Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced  that the Company has been awarded Phase I of a Fast Track Small Business  Innovation Research Grant (SBIR) from the National Institutes of Health  (NIH) to support the development of the Company's program for  aerosolizing KL4 surfactant for neonatal respiratory distress syndrome  (RDS). The Company submitted a proposal, with a total budget of $2.4  million, for the development of the Company's proprietary capillary  aerosol generating (CAG) device technology followed by a Phase 2a  clinical trial of aerosolized KL4 surfactant in preterm infants with or  at risk for RDS. The Phase I grant provides  $580,000 to support development efforts. The Company anticipates the  potential awarding of the Phase II grant, up to an additional $1.8  million, following the conclusion of Phase I activities.
 
 Dr. Robert Segal, Discovery Labs' Senior Vice President and the Grant  Principal Investigator commented, "We are extremely pleased that the NIH  has recognized the importance of our aerosolized KL4 surfactant  technology, which has the potential to significantly improve the  management of preterm infants with or at risk for RDS and make it  possible for many more preterm infants to be treated with surfactant  therapy."
 
RDS is one of the most prevalent medical issues  facing premature infants in the neonatal intensive care unit and is a  condition in which premature infants are born with a lack of natural  lung surfactant and are unable to breathe. Approximately 360,000 low  birth weight premature infants are born annually in the United States  and at risk for RDS. Premature babies with RDS often require  endotracheal intubation and mechanical ventilation. In many cases,  currently available animal-derived surfactants are administered while  the child is intubated. Neonatologists often try to avoid intubation and  mechanical ventilation in preterm infants due to well established  medical risks associated with these procedures. As a result, many  neonatologists reserve intubation for infants with severe respiratory  distress, where the benefits of invasive procedures clearly outweigh the  associated risks.  The Company believes that the neonatal medical  community increasingly recognizes the potential benefits of a synthetic,  peptide-containing surfactant, and a less-invasive method of delivering  surfactant, such as aerosolized KL4 surfactant.  
 
KL4  surfactant is a completely synthetic, peptide-containing surfactant  designed to closely mimic the essential attributes of human lung  surfactant. Discovery Labs is developing aerosolized KL4 surfactant for  delivery in conjunction with non-invasive nasal continuous positive  airway pressure (nCPAP) and other ventilation modalities. Aerosurf®, the  Company's initial aerosolized KL4 surfactant product, holds the promise  to significantly expand the use of surfactant therapy in at-risk  premature infants by potentially providing neonatologists with a means  of administering surfactant without the risks currently associated with  surfactant administration. The Company believes that Aerosurf, if  approved, will allow for a potentially significant increase in the  number of infants who will benefit from surfactant therapy.
 
 Discovery Labs' lead KL4 surfactant product, Surfaxin® for neonatal RDS,  has been previously demonstrated to be generally safe and effective in a  large multi-national Phase 3 clinical program. Surfaxin is the subject  of a Complete Response letter from the U.S. Food and Drug Administration  (FDA) and Discovery Labs expects to submit a complete response to the  FDA in the first quarter of 2011. If approved, Surfaxin would be the  first synthetic, peptide-containing surfactant for commercial use in  neonatal medicine.
 
Surfaxin and Aerosurf are investigational  drugs that have not been approved by the U.S. FDA or any other world  health regulatory authorities.